Clinical significance of peripheral blood CD4+ T cell subpopulations for immune checkpoint inhibitor treatment

Clinical significance of peripheral blood CD4+ T cell subpopulations for immune checkpoint inhibitor treatment - peripheral blood CD4+ T cell subpopulations for immune checkpoint inhibitor treatment

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041803

Enrollment

120

Registered

2020-09-20

Start date

2020-09-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with gastrointestinal, hepatobilial, urological, or otorhinolaryngological cancer treated with an immune chekpoint inhibitor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients whom written informed consents of the study are obtained from

Exclusion criteria

Exclusion criteria: patients with past history of an immune checkpoint inhibitor

Design outcomes

Primary

Measure	Time frame
overall survival	—

Secondary

Measure	Time frame
progression-free survival objective response rate adverse events during the treatment	—

Countries

Japan

Contacts

Public ContactYoshimichi Haruna

Osaka General Medical Center Department of Laboratory Medicine

apple-123-grape@ab.auone-net.jp06-6692-1201

Outcome results